Abstract: Chronic myeloid leukemia (CML) and Non-Hodgkin Lymphoma (NHL) are two different origins of hematological malignancies, which rarely occur at the same time. Moreover, NHL secondary to CML is common in T cell lymphoma, while NHL of B cell origin is rare. Since 1999, only 22 cases with B cell lymphoma have been reported, of which 4 cases have diffuse large B-cell lymphoma (DLBCL). The lesions of DLBCL were in lymph node, liver, jejunum, and soft palate. To our knowledge, it has no report for the primary gastric DLBCL (PG-DLBCL) occurring in CML. Here we reported a 63-year-old man of chronic phase (CP) CML associated with PG-DLBCL. The patient was diagnosed with CML nearly eight years ago and was treated with imatinib and nilotinib successively. However, gastroscopy found malignant lesions in the patient's stomach in March 2018, and the masses were diagnosed as PG-DLBCL. Subsequently, with the treatment of the RCOP + lenalidomide regimen chemotherapy for 3 cycles, the patient achieved nearly complete remission (CR).
Introduction
Chronic myelogenous leukemia (CML) is a common malignant tumor in the hematopoietic system. The incidence of CML is about 10-12/100,000 1 every year in the world.
With the increase of age, the incidence of CML tends to increase gradually. CML is characterized by the presence of the Philadelphia chromosome (Ph) (t(9;22)(q34;q11.2)) and the fusion gene of breakpoint cluster/Abelson tyrosine kinase (BCR/ABL), 2 and it is divided into three stages according to its clinical characteristics: chronic phase (CP), accelerated phase (AP) and blast crisis (BC). 2 The treatment for CML used to be only relied on chemotherapy (hydroxyurea, busulfan, etc.) or interferon-alfa (IFN-α) to control their condition for a long time, although the efficacy of this treatment scheme is not ideal.
Recently the allogeneic stem cell transplantation (allo-SCT) showed curative to CML, but only a few patients can benefit from allo-SCT because of the limitation of donor source, age, and so on. 3 Since the first generation tyrosine kinase inhibitor (TKI) -imatinib mesylate (IM) is approved by the FDA (Food and Drug Administration) as the first-line treatment of CML-CP in 2001, it has been used for more than 10 years. TKI treatment results in great improvement of the prognosis of CML-CP patients, particularly the long-term use of TKI has obtained signfiicant results, eight years Overall Survival (OS) was close to 92%. 4 However, the continued use of these drugs may increase the risk of secondary malignancies. 5 It is reported that CML patients are prone to complicate with acute leukemia or lymphoma due to chromosome changes. 6 In addition, some experts have demonstrated that simultaneous T cell lymphoma and myeloid leukemia is more than simultaneous B cell lymphoma and myeloid. 7, 8 Primary gastric lymphoma (PGL) is an uncommon tumor, accounting for approximately 10% of gastric malignant tumors and about 5% of all lymphomas. 9, 10 However, PGL is the second most common malignant tumors in gastric cancer. 9 Furthermore, PGL is one of the most common extranodal lymphomas, which accounts for 30-50% of primary extranodal lymphomas. 10 The most common pathological type of PGL is primary gastric diffuse large Bcell lymphoma (PG-DLBCL), followed by mucosa-associated lymphoid tissue(MALT 2018. The MRI scan of the brain showed acute cerebral infarction of right cerebral hemisphere, multiple sulcus in the brain. Continued with the symptomatic treatment, the patient's gastric biopsy tissue was re-examined by the pathology department of our hospital, and it was primarily diagnosed as a non-germinal center DLBCL (non-GCB). Figure  2A ) was performed and showed no evidence of lymphoma infiltration except for malignant lesions at the bottom of the stomach. There was no abnormal change in liquid biopsy and ABL kinase mutation.
63%). Positron emission tomography (PET) (
In conclusion, the patient can be diagnosed as CML-CP (complete hematological remission, CHR) with PG- DLBCL (Ann Arbor staging system:IIEA, IPI score:4, Lugano staging system:I) and acute cerebral infarction. The patient was an elderly male with acute cerebral infarction, long-term bed rest, poor appetite, and low immune function, also the pathological type of DLBCL in the patient belonged to non-germinal center subtype; in order to prevent the increase of cardiac and bone marrow toxicity of anthracycline -doxorubicin, he was treated with RCOP and Lenalidomide (rituximab 375 mg/m 2 d0, cyclophosphamide 750 mg/m 2 d1, vindesine 2.5 mg/m 2 d1, dexamethasone 0.75 mg/m 2 d1-5, lenalidomide 10 mg d1-21) regimen chemotherapy every 28 days from April 2018 to July 2018. Considering that chronic and poor general condition and the unstable blood cell count before chemotherapy, and also reducing the risk of bone marrow suppression resulted from the combination therapy, nilotinib was continuously administered with a dose of 400 mg once daily. Three cycles later, PET ( Figure 2B ) showed that there was no clear active tumor tissue in the whole body, which suggested that the patient achieved nearly complete remission (CR) from PG-DLBCL. However, the presence of BCR/ABL P210 transcripts with a positive rate of 61% was detected by FISH in bone marrow cells. In order to achieve a better therapeutic efficacy on CML, the dose of nilotinib was subsequently increased to 400 mg twice daily. The chemotherapy regimen was adjusted to RP (rituximab 375 mg/m 2 d0, dexamethasone 0.75 mg/m 2 d1-5) for three courses due to the low blood cell counting of the patient during the past three cycles of chemotherapy, and the patients' blood routine gradually returned to normal, and the patient restored the RCOP regimen chemotherapy in December 2018. In the scheme, dexamethasone is selected in place of prednisolone owing to the patient had poor appetite and stomach discomfort, which would avoid the additional gastrointestinal burden associated with large doses of prednisone. Unfortunately, although the condition improved after the active treatment, the patient refused the ongoing therapy for the fear of chemotherapy.
Discussion
CML and Non-Hodgkin lymphoma (NHL) belong to malignant tumors with different origins. NHL is rare in CML; the majorities are T cell lymphomas with an immature thymic phenotype, while B cell lymphomas are much rare. 7, 12 With literature search, we found only twenty-two cases of B cell lymphomas occurring in patients with CML in the PUBMED since 1999 ( The patient showed the positive expression of CD20 and the pathological type of non-germinal center subtype, therefore RCOP combined with lenalidomide regimen was used. After three cycles of the treatment, PET showed that the gastric mass disappeared and the curative effect reached the basic CR. However, the FISH test indicates that BCR/ABL is higher than before, indicating the chemotherapy sheme is not ideal for CML; after increasing the dose of nilotinib and reducing the chemotherapeutic regimen, the patient condition was stable. This suggested it also needs to minitor the progress of CML and pay attention to CML treatment while treatment of lymphoma. Our chemothrepay scheme alteration showed a stable efficacy for the patient, which may give some hints for the treatment of this type of patients. PGL is an uncommon type of gastrointestinal tumor; and the most common pathological type of PGL is PG-DLBCL, 11 which is mostly primary and can also be transformed from other types such as MALT and small B-cell lymphoma. Aleman B M P reported that PG-DLBCL was mostly seen in middle-aged and elderly men, mainly in the early stage, and the pathological subtypes were mostly non-GCB. This present case is consistent with the above characteristics. 37 PG-DLBCL represents a heterogeneous subset of NHL that demonstrates many molecular alterations and somatic mutations. The efficacy of PG-DLBCL treatment remains controversial. Surgery had been used as a first-line treatment for PG-DLBCL. However, studies have shown that radical gastrectomy for PG-DLBCL is controversial and considered unnecessary, which is recommended as an emergency treatment for severe perforation or bleeding. 38 Studies have shown that rituximab can significantly improve the prognosis of DLBCL. 39 Among the five patients with CML and DLBCL, three patients survived well until the publication of the journal after using the combination therapy of rituximab (RCHOP, R-EPOCH, and RCOP+ lenalidomide, respectively), while the other two had poor outcomes and died of complications. This report supports the rituximab effect on this type of patients although some reports argued that rituximab did not improve the survival rate of extranodal DLBCL patients. 40 Lenalidomide has been widely used as an immunomodulatory drug in multiple myeloma and myelodysplastic syndrome, it is also reported that it can also be used in DLBCL patients in recent years, especially in non-GCB patients with poor prognosis, which can improve their prognosis. [41] [42] [43] Lenalidomide has promoting immunity effect by stimulating natural killer cells to enhance the natural immune system to increase its antitumor activity and inhibit angiogenesis. 44 Our data showed that a combined treatment regimen of RCOP and lenalidomide achieved the CR for the patient, indicating this regimen is an effective therapy for treatment of primary gastric DLBCL (PG-DLBCL) with CML. Our data also support the above viewpoint that rituximab and lenalidomide have therapeutic effect on DLBCL. TKI has been used as the first-line treatment for CML for more than ten years, and its effect is remarkable. However, long-term use of TKI may lead to the risk of secondary malignancies. It has been shown that imatinib inhibits the effector function of T-lymphocytes and injures the differentiation of peripheral blood progenitor cells into dendritic cells. 45 However, some scholars reported that long-term use of TKI did not increase the risk of carcinogenesis compared with the general population. 46 Furthermore, analysis of patient data from multiple phase I and II trials at the MD Anderson Cancer Center, who were treated with TKI for CML, revealed a risk of secondary malignancies that was lower than expected in the healthy population. 47 Even so, the chromosome mutation in CML patients suggests that the unstable function of stem progenitor cells is still a high risk factor for carcinogenesis. 6 Therefore, we still need to be vigilant and strengthen regular follow-up in the process of diagnosis and treatment of CML patients.
In 2015, Bohers et al first validated that liquid biopsy could be used to assist diagnosis and prognosis judgment during the examination of DLBCL patient. 48 Although no positive results were found in the reported patient, more attention should be paid to liquid biopsy in the diagnosis of lymphoma in the future. As a non-invasive diagnostic method, liquid biopsy has unique advantages in early and precise diagnosis and prognosis, evaluation. Tissue biopsy is limited by the location of biopsy, while liquid biopsy may find gene expression that cannot be found by tissue biopsy, which is very helpful to monitor the patient's condition. [49] [50] [51] A liquid biopsy will be widely used in the furture to better monitor minimal residual disease (MRD), by which lymphoma could be completely eradicate.
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Conclusion
The patient with simultaneous occurrence of CML and PG-DLBCL is a very rare case, and this is first reported for the primary gastric DLBCL (PG-DLBCL). Combination of Rituximab and lenalidomide is an effective therapy for the patients with this type of disease. The effect of this treatment on survival need to be further investigated in a big cohort in the future. Although there is no clear pathogenic link between CML and PG-DLBCL, we still recommend that disease surveillance should be strengthened during TKI treatment.
